Upgrade to SI Premium - Free Trial

Medicus Pharma (MDCX)

0.17 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/20/26)

Latest Headlines

Form 424B3 Medicus Pharma Ltd. August 13, 2026 6:04 AM - SEC Filing Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update August 12, 2026 6:01 PM - StreetInsider Form 10-Q Medicus Pharma Ltd. For: Jun 30 August 12, 2026 5:20 PM - SEC Filing Medicus Pharma names Dr. Faisal Mehmud CEO of UK unit Antev August 3, 2026 7:31 AM - StreetInsider Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom August 3, 2026 7:30 AM - StreetInsider Medicus Pharma gets UAE approval for endometriosis drug study July 31, 2026 7:30 AM - StreetInsider Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis July 31, 2026 7:30 AM - StreetInsider Alliance Global Partners Starts Medicus Pharma Ltd. (MDCX) at Buy July 28, 2026 7:08 AM - StreetInsider Medicus Pharma gets FDA clearance to start Gorlin Syndrome study July 27, 2026 8:17 AM - StreetInsider Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome July 27, 2026 8:17 AM - StreetInsider Medicus Pharma gets FDA feedback and IRB nod for smaller Phase 2 trial July 16, 2026 7:30 AM - StreetInsider Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention July 16, 2026 7:30 AM - StreetInsider New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group July 4, 2026 12:27 PM - StreetInsider Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026 June 22, 2026 7:30 AM - StreetInsider New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA June 20, 2026 1:30 PM - StreetInsider Medicus Pharma submits rare pediatric disease designation request for SkinJect June 15, 2026 7:30 AM - StreetInsider Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome June 15, 2026 7:30 AM - StreetInsider New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA June 12, 2026 2:45 PM - StreetInsider Medicus Pharma starts genomic endometriosis trial in UAE June 11, 2026 7:30 AM - StreetInsider Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program June 11, 2026 7:30 AM - StreetInsider Medicus Pharma submits European filing for Teverelix prostate cancer study June 8, 2026 7:32 AM - StreetInsider Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission June 8, 2026 7:30 AM - StreetInsider Full Article List